NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future
In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro
‘Be Careful We’re Not Fighting Old Battles’ On Study Section Issue
‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’
“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s
Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants
Broder Not Satisfied With Mortality STATS On Three Major Cancers
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









